Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
April 15 2024 - 6:00AM
Business Wire
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer
screening and diagnostic tests, announced today the appointment of
Aaron Bloomer as chief financial officer (CFO), effective May 15,
2024.
Mr. Bloomer brings to Exact Sciences more than 15 years of
finance and accounting experience. He previously held leadership
positions at Baxter International and 3M, where he helped improve
financial results, drove operational rigor, led strategic growth
initiatives, played key roles in portfolio management,
acquisitions, and divestitures, and set corporate strategy and
vision. At Baxter, Mr. Bloomer led corporate financial planning,
reporting, and analytics (FP&A) as vice president. Prior to
that, he spent more than a decade at 3M, where he served as senior
vice president of FP&A, as well as CFO for 3M China and one of
the company’s divisions in Tokyo, Japan.
“Aaron comes to us with significant global experience setting
corporate strategy and driving growth and operational discipline
from his leadership roles at incredible companies,” said Kevin
Conroy, chairman and chief executive officer of Exact Sciences. “We
are excited to welcome a leader of Aaron’s caliber to our executive
team. As we look to bring our portfolio of tests to more patients
around the world, Aaron’s oversight will help us further our
mission of helping to eradicate cancer by preventing it, detecting
it earlier, and guiding personalized treatment.”
To help facilitate a smooth transition, Mr. Bloomer joins the
company as executive vice president, finance, effective
immediately, and will succeed Jeff Elliott following a 30-day
transition period. As previously announced, Mr. Elliott will then
transition to serving as special advisor to the chief executive
officer.
“I am energized by the opportunity to join a company with such
an important mission and to play a meaningful role in Exact
Sciences’ growth trajectory,” said Mr. Bloomer. “Throughout my
career, I have applied a relentlessly competitive and innovative
mindset to drive growth and success. I plan to do the same as CFO,
with a focus on superior financial and operational execution.”
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests,
Exact Sciences gives patients and health care professionals the
clarity needed to take life-changing action earlier. Building on
the success of the Cologuard® and Oncotype® tests, Exact Sciences
is investing in its pipeline to develop innovative solutions for
use before, during, and after a cancer diagnosis. For more
information, visit ExactSciences.com, follow Exact Sciences on X
(formerly known as Twitter) @ExactSciences, or find Exact Sciences
on LinkedIn and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240415750010/en/
Investor Contact: Nathan Harrill Exact Sciences Corp.
investorrelations@exactsciences.com 608-535-8659
Media Contact: Morry Smulevitz Exact Sciences Corp.
msmulevitz@exactsciences.com 608-345-8010
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Jul 2024 to Aug 2024
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Aug 2023 to Aug 2024